LAG3 and melanoma: In melanoma, patients with ≥ 1% LAG-3+ cells in their tumors had significantly longer PFS compared to patients with < 1% LAG-3 expression. No significant difference was observed in overall survival between the two groups (269).Further evaluation of LAG-3 and PD-L1 to determine their roles as predictive biomarkers for response to Opdualag might be beneficial.